Stoke Therapeutics (STOK) Common Equity: 2022-2025
Historic Common Equity for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $308.1 million.
- Stoke Therapeutics' Common Equity rose 32.74% to $308.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year increase of 32.74%. This contributed to the annual value of $229.0 million for FY2024, which is 43.53% up from last year.
- Latest data reveals that Stoke Therapeutics reported Common Equity of $308.1 million as of Q3 2025, which was down 8.01% from $334.9 million recorded in Q2 2025.
- Over the past 5 years, Stoke Therapeutics' Common Equity peaked at $350.1 million during Q1 2025, and registered a low of $140.3 million during Q1 2024.
- For the 3-year period, Stoke Therapeutics' Common Equity averaged around $234.0 million, with its median value being $229.0 million (2024).
- As far as peak fluctuations go, Stoke Therapeutics' Common Equity slumped by 34.37% in 2024, and later skyrocketed by 149.44% in 2025.
- Stoke Therapeutics' Common Equity (Quarterly) stood at $184.8 million in 2022, then declined by 13.68% to $159.6 million in 2023, then surged by 43.53% to $229.0 million in 2024, then soared by 32.74% to $308.1 million in 2025.
- Its Common Equity stands at $308.1 million for Q3 2025, versus $334.9 million for Q2 2025 and $350.1 million for Q1 2025.